A double‐blind, randomized, placebo‐controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing‐remitting multiple sclerosis

OBJECTIVE: Inhibition of dihydroorotate dehydrogenase suppresses magnetic resonance imaging brain lesions and disease activity in multiple sclerosis but has limiting tolerability. We assessed the safety and efficacy of vidofludimus calcium, a novel, selective dihydroorotate dehydrogenase inhibitor,...

Descripción completa

Detalles Bibliográficos
Autores principales: Fox, Robert J., Wiendl, Heinz, Wolf, Christian, De Stefano, Nicola, Sellner, Johann, Gryb, Viktoriia, Rejdak, Konrad, Bozhinov, Plamen Stoyanov, Tomakh, Nataliya, Skrypchenko, Iryna, Muehler, Andreas R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268865/
https://www.ncbi.nlm.nih.gov/pubmed/35698927
http://dx.doi.org/10.1002/acn3.51574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268865/
https://www.ncbi.nlm.nih.gov/pubmed/35698927
http://dx.doi.org/10.1002/acn3.51574

Ejemplares similares